Literature DB >> 9317177

The National Cancer Data Base report on race, age, and region variations in prostate cancer treatment.

C J Mettlin1, G P Murphy, M P Cunningham, H R Menck.   

Abstract

BACKGROUND: Patterns of care for prostate cancer patients in the United States have changed as early detection has improved. The National Cancer Data Base of the American College of Surgeons Commission on Cancer provides information about the treatment of patients in all age, race, and regional groups from institutions that represent cancer care at the community level as well as in medical centers.
METHODS: Data on 251,416 prostate cancer patients diagnosed between 1992 and 1994 were studied. Patient and disease characteristics, including age, race, the geographic region from which a case was reported, American Joint Committee on Cancer stage, and tumor grade were related to the primary pattern of treatment. Stage-standardized comparisons were made among different age groups, race groups, and regional groups.
RESULTS: Stage and tumor grade varied little across age, race, and regional classifications. African American patients were more likely than white patients to have Stage IV prostate cancer at the time of diagnosis. Men older than 75 years had greater proportions than younger men of both the earliest and the most advanced stages of cancer. Overall, 24.6% of patients received no cancer-directed therapy, 11.6% were treated with hormones or endocrine surgery, 28.6% received radiation therapy, 28.3% underwent radical prostatectomy, and 6.9% were treated by other modalities or combinations of modalities. Treatment patterns varied markedly by age. The selection of radical prostatectomy relative to no treatment and radiation therapy varied by race and region.
CONCLUSIONS: The results of this study showed that prostate cancer treatment varies by patient age, race, and geographic region. The reasons for some of these variations are not well understood and deserve further investigation.

Entities:  

Mesh:

Year:  1997        PMID: 9317177

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  28 in total

1.  Patterns of prostate cancer treatment by clinical stage and age.

Authors:  D Meltzer; B Egleston; I Abdalla
Journal:  Am J Public Health       Date:  2001-01       Impact factor: 9.308

2.  Race/ethnicity and the receipt of watchful waiting for the initial management of prostate cancer.

Authors:  Vickie L Shavers; Martin L Brown; Arnold L Potosky; Carrie N Klabunde; W W Davis; Judd W Moul; Angela Fahey
Journal:  J Gen Intern Med       Date:  2004-02       Impact factor: 5.128

3.  African-American Men with Low-Risk Prostate Cancer: Modern Treatment and Outcome Trends.

Authors:  Augustine C Obirieze; Ambria Moten; Delenya Allen; Chiledum A Ahaghotu
Journal:  J Racial Ethn Health Disparities       Date:  2014-12-16

4.  Managed care market share and primary treatment for cancer.

Authors:  Nancy L Keating; Mary Beth Landrum; Ellen Meara; Patricia A Ganz; Edward Guadagnoli
Journal:  Health Serv Res       Date:  2006-02       Impact factor: 3.402

5.  Racial, Socioeconomic, and Geographic Disparities in the Receipt, Timing to Initiation, and Duration of Adjuvant Androgen Deprivation Therapy in Men with Prostate Cancer.

Authors:  Chi Nguyen; David R Lairson; Michael D Swartz; Xianglin L Du
Journal:  J Racial Ethn Health Disparities       Date:  2018-06-29

Review 6.  Systemic therapies for metastatic renal cell carcinoma in older adults.

Authors:  Sumanta K Pal; Ari Vanderwalde; Arti Hurria; Robert A Figlin
Journal:  Drugs Aging       Date:  2011-08-01       Impact factor: 3.923

7.  Are HIV-infected men vulnerable to prostate cancer treatment disparities?

Authors:  Adam B Murphy; Ramona Bhatia; Iman K Martin; David A Klein; Courtney M P Hollowell; Yaw Nyame; Elodi Dielubanza; Chad Achenbach; Rick A Kittles
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2014-07-25       Impact factor: 4.254

8.  Relationships among primary tumor size, number of involved nodes, and survival for 8044 cases of Merkel cell carcinoma.

Authors:  Jayasri G Iyer; Barry E Storer; Kelly G Paulson; Bianca Lemos; Jerri Linn Phillips; Christopher K Bichakjian; Nathalie Zeitouni; Jeffrey E Gershenwald; Vernon Sondak; Clark C Otley; Siegrid S Yu; Timothy M Johnson; Nanette J Liegeois; David Byrd; Arthur Sober; Paul Nghiem
Journal:  J Am Acad Dermatol       Date:  2014-02-09       Impact factor: 11.527

9.  Referral patterns and treatment choices for patients with hepatocellular carcinoma: a United States population-based study.

Authors:  Omar Hyder; Rebecca M Dodson; Hari Nathan; Joseph M Herman; David Cosgrove; Ihab Kamel; Jean-Francois H Geschwind; Timothy M Pawlik
Journal:  J Am Coll Surg       Date:  2013-09-13       Impact factor: 6.113

10.  Factors associated with initial treatment and survival for clinically localized prostate cancer: results from the CDC-NPCR Patterns of Care Study (PoC1).

Authors:  Maria J Schymura; Amy R Kahn; Robert R German; Mei-Chin Hsieh; Rosemary D Cress; Jack L Finch; John P Fulton; Tiefu Shen; Erik Stuckart
Journal:  BMC Cancer       Date:  2010-04-19       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.